Search

Your search keyword '"Antimitotic agents -- Conferences, meetings and seminars"' showing total 378 results
Start Over Descriptor "Antimitotic agents -- Conferences, meetings and seminars"
378 results on '"Antimitotic agents -- Conferences, meetings and seminars"'

1. Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation ANUPAM RAMA, MODERATOR, JP MORGAN SECURITIES LLC: All right, let's go ahead and get started. Welcome everybody to the JP Morgan Healthcare Conference. My name is Anupam Rama. I'm [...]

Published
2025

2. Exelixis Inc at JPMorgan Healthcare Conference - Final

Subjects
Exelixis Inc. -- Conferences, meetings and seminars, Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

Presentation ALEX MORRISON, ANALYST, J.P. MORGAN SECURITIES LLC: Good afternoon, everyone. My name is Alex Morrison. I am an associate with JPMorgan's Healthcare Investment Banking team. Today, it's my pleasure [...]

Published
2025

3. Nuvation Bio Inc at JPMorgan Healthcare Conference - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars, Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Kinase inhibitors -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Alectinib -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

Presentation NATALIE COLLINS, ANALYST, JP MORGAN: Hi, everyone and welcome to the 43rd annual JPMorgan Healthcare Conference. My name is Natalie Collins and I'm an associate on the JPMorgan Healthcare [...]

Published
2025

4. Event Brief of Exelixis Inc at Piper Sandler Healthcare Conference - Final

Subjects
Exelixis Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

CORPORATE PARTICIPANTS . Andrew Peters - Exelixis Inc,Vice President, Strategy CONFERENCE CALL PARTICIPANTS . Joe Catanzaro - Piper Sandler,Analyst OVERVIEW Company Summary FINANCIAL DATA PRESENTATION Presentation 1. So second half [...]

Published
2024

5. Exelixis Inc at Piper Sandler Healthcare Conference - Final

Subjects
Exelixis Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation JOE CATANZARO, ANALYST, PIPER SANDLER: Great. Well, thanks, everybody, for joining us here of day one Annual Piper Sandler Healthcare Conference. I'm Joe Catanzaro, one of the biotech analysts [...]

Published
2024

6. Eli Lilly and Co at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Eli Lilly and Co. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business, Verzenio (Medication)
Abstract

Presentation TERENCE FLYNN, ANALYST, MORGAN STANLEY: Good morning everybody. Thanks for joining us. I'm Terence Flynn, the US biopharma analyst here at Morgan Stanley. Very pleased to be hosting Eli [...]

Published
2024

7. Olema Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Officials and employees -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation ANTHONY YU, EXECUTIVE DIRECTOR, MORGAN STANLEY: Thanks, everyone, for joining us today. My name is Anthony Yu, I'm an Executive Director in Morgan Stanley's Healthcare team. I'm joined here [...]

Published
2024

8. Event Brief of Exelixis Inc at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Exelixis Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Liver cancer -- Conferences, meetings and seminars, Liver -- Conferences, meetings and seminars, Thyroid cancer -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business
Abstract

CORPORATE PARTICIPANTS . Michael Morrissey - Exelixis Inc,President, Chief Executive Officer, Director CONFERENCE CALL PARTICIPANTS . Jeff Hung - Morgan Stanley,Analyst OVERVIEW Company Summary FINANCIAL DATA PRESENTATION Presentation 1. A [...]

Published
2024

9. Exelixis Inc at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Exelixis Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business
Abstract

Presentation JEFF HUNG, ANALYST, MORGAN STANLEY: Welcome to the Morgan Stanley Global Healthcare Conference. Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research [...]

Published
2024

10. HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, AstraZeneca PLC -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Fruzaqla (Medication)
Abstract

Presentation PAUL CHOI, ANALYST, GOLDMAN SACHS GROUP, INC.: Okay. Good afternoon. We'll continue with the next session. I'm Paul Choi, and I cover the SMid Cap Biotechnology sector here at [...]

Published
2024

11. Exelixis Inc at William Blair Growth Stock Conference - Final

Subjects
Exelixis Inc. -- Conferences, meetings and seminars -- Growth, William Blair and Company L.L.C. -- Conferences, meetings and seminars -- Growth, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars -- Growth, Stocks -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars -- Growth, Antimitotic agents -- Conferences, meetings and seminars, Company growth, Securities industry, Business, Cabometyx (Medication)
Abstract

Presentation ANDY HSIEH, ANALYST, WILLIAM BLAIR & COMPANY, L.L.C.: All right. So welcome back. Thanks for joining us today at 44 Growth Stock conference. I'm Andy Hsieh, one of the [...]

Published
2024

12. The Hsuyu Pharmaceutical Institute's 2025 Annual Meeting has been successfully concluded! - GMP certified EU-certified injectable antitumor drug

Subjects
Conferences, meetings and seminars, Colorectal cancer -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars
Abstract

Key Highlights: * The Hsuyu Pharmaceutical Institute's 2025 Annual Meeting focused on innovation and global expansion * Dr. Ding Zhi, Chairman and President, and over 600 employees attended the meeting [...]

Published
2025

13. Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers

Subjects
Inqovi (Medication), Care and treatment, Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars, Cancer research -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars -- Care and treatment, Antineoplastic agents -- Conferences, meetings and seminars, Decitabine -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Cancer -- Care and treatment -- Conferences, meetings and seminars -- Research, Antimitotic agents -- Conferences, meetings and seminars
Abstract

2024 DEC 24 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Taiho Oncology, Inc., presented results of two studies focused on oral therapies for patients with [...]

Published
2024

14. Menarini Group Presents New and Expanded Data at the 2024 San Antonio Breast Cancer Symposium Reinforcing the Role of ORSERDU[R] (Elacestrant) for Patients with ER+, HER2- Advanced or Metastatic Breast Cancer (mBC)

Subjects
Stemline Therapeutics Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Business, international, Orserdu (Medication)
Abstract

* Real-world evidence bolsters the efficacy of ORSERDU for the treatment of patients with ER+/HER2- ESR1-mut advanced or mBC. * Updated results of elacestrant in combination with abemaciclib show favorable [...]

Published
2024

15. Event Brief of HUTCHMED (China) Limited Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM - Final

Subjects
Banks (Finance) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, B cells -- Conferences, meetings and seminars, Questions and answers -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

CORPORATE PARTICIPANTS . David Ng - HUTCHMED (China) Limited,Head of IR & Capital Strategies . Ming Shi - HUTCHMED (China) Limited,Executive VP, Head of R&D and Chief Medical Officer CONFERENCE [...]

Published
2024

16. HUTCHMED (China) Ltd at Bank of America Healthcare Conference - Final

Subjects
Bank of America Corp. -- Officials and employees -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Strategic planning (Business) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Officials and employees -- Conferences, meetings and seminars, B cells -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business
Abstract

Presentation ALEC STRANAHAN, ANALYST, BOFA SECURITIES: Thanks for joining this session with HUTCHMED. My name is Alec Stranahan. I'm Vice President and senior biotech analyst covering HUTCHMED here at BofA. [...]

Published
2024

17. HUTCHMED (China) Limited Presents at Bank of America Health Care Conference 2024, May152024 02:20 PM - Final

Subjects
Bank of America Corp. -- Officials and employees -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Strategic planning (Business) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Officials and employees -- Conferences, meetings and seminars, B cells -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business
Abstract

Presentation ALEC WARREN STRANAHAN, ASSOCIATE, BOFA SECURITIES, RESEARCH DIVISION: All right. Great. Hey, everyone. Good afternoon, and welcome to day 2 of the 2024 Bank of America Healthcare Conference. Thanks [...]

Published
2024

18. Olema Pharmaceuticals Inc at Bank of America Health Care Conference - Final

Subjects
Bank of America Corp. -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business
Abstract

Presentation TAZEEN AHMAD, ANALYST, BANK OF AMERICA: Okay. Good afternoon, everybody. Thanks so much for continuing to participate in the Bank of America Health Care Conference. I'm Tazeen Ahmad. I'm [...]

Published
2024

19. Mayor at the symposium 'Artificial Intelligence for a human cancer medicine'

Subjects
Artificial intelligence -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Mayors -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Artificial intelligence, Business, international
Abstract

Essen: Essen, Germany has issued the following news release: On Thursday, June 27, Mayor Thomas Kufen, together with Prime Minister Hendrik Wust and NRW Science Minister Ina Brandes, met with [...]

Published
2024

20. C4 Therapeutics Inc at JPMorgan Healthcare Conference - Final

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation ERIC JOSEPH JPMORGAN, MODERATOR: All right. Good morning. I'm Eric Joseph, senior biotech analyst at JPMorgan. And our next presenting company this morning is C4 Therapeutics. Presenting on behalf [...]

Published
2024

21. C4 Therapeutics Inc at JPMorgan Healthcare Conference - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business
Abstract

Presentation ERIC JOSEPH, ANALYST, J.P. MORGAN SECURITIES LLC: All right. Good morning. I'm Eric Joseph, senior biotech analyst at J.P. Morgan. And our next presenting company this morning is C4 [...]

Published
2024

22. Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference - Final

Subjects
Financial analysts -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Web sites -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Company Web site/Web page, Business
Abstract

Presentation ANUPAM RAMA, ANALYST, JPMORGAN SECURITIES, INC.: All right. Let's go ahead and get started. Welcome, everybody, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm [...]

Published
2024

23. Olema Pharmaceuticals Inc at JPMorgan Healthcare Conference - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Conferences, meetings and seminars, Web sites -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Company Web site/Web page, Banking industry, Business
Abstract

Presentation ANUPAM RAMA J.P. MORGAN & CO., ANALYST: Our ID. Let's go ahead and get started. Welcome everybody, to the 42nd Annual JP Morgan Healthcare Conference. My name is Anupam [...]

Published
2024

24. Event Brief of Exelixis Inc Corporate R&D Day - Final

Subjects
Exelixis Inc. -- Conferences, meetings and seminars, William Blair and Company L.L.C. -- Conferences, meetings and seminars, Financial analysts -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Product development -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Time to market, Business
Abstract

CORPORATE PARTICIPANTS . Amy C. Peterson - Exelixis, Inc.,Executive VP, Product Development & Medical Affairs and Chief Medical Officer . Dana T. Aftab - Exelixis, Inc.,Executive VP of Discovery and [...]

Published
2023

25. Lilly Announces Details of Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Verzenio (Medication), Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Verzenio(r) (abemaciclib; a CDK4/6 inhibitor), Retevmo(r) [...]

Published
2024

26. Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Subjects
Qualigen Therapeutics Inc. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Societies -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Cancer -- Research, Associations, institutions, etc. -- Conferences, meetings and seminars, Pancreatic cancer -- Conferences, meetings and seminars -- Drug therapy, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ('Qualigen' or the 'Company,' Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel [...]

Published
2024

27. Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference - Final

Subjects
Pfizer Inc. -- Conferences, meetings and seminars, Cantor Fitzgerald L.P. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation LI WATSEK, ANALYST, CANTOR FITZGERALD, L.P.: All right, guys, welcome to the fireside chat with Arvinas. I'm Li Watsek, a biotech analyst at Cantor. So I'm very pleased today [...]

Published
2023

28. Olema Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference - Final

Subjects
Cantor Fitzgerald L.P. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Estrogen -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business, Tagrisso (Medication)
Abstract

Presentation JOSH SCHIMMER, ANALYST, CANTOR FITZGERALD & CO.: Alright, there we go. I think we're ready to start. I'm very excited to kick off the last session with a topic [...]

Published
2023

29. Exelixis Inc at Morgan Stanley Global Healthcare Conference - Final

Subjects
Morgan Stanley -- Conferences, meetings and seminars, Exelixis Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Blood coagulation factors -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business
Abstract

Presentation JEFF HUNG, EQUITY ANALYST, MORGAN STANLEY, RESEARCH DIVISION: Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analyst. For important disclosures, please see [...]

Published
2023

30. Merus NV at Citi BioPharma Conference - Final

Subjects
Citigroup Inc. -- Conferences, meetings and seminars, Biological products industry -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Financial services industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Financial services industry, Business
Abstract

Presentation YIGAL NOCHOMOVITZ, MODERATOR, CITIGROUP INC.: So second to last session of the day, I got [Yamaha Tarvitz] That's one of the biotech analysts here at Citi. It's my pleasure [...]

Published
2023

31. Arvinas Inc at Goldman Sachs Healthcare Conference - Final

Subjects
The Goldman Sachs Group Inc. -- Conferences, meetings and seminars, Pfizer Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Investment banks -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation MADHU SUDHAN KUMAR, RESEARCH ANALYST, GOLDMAN SACHS GROUP, INC., RESEARCH DIVISION: All right. Thanks, everyone, for joining us this afternoon in the Goldman Sachs Global Healthcare Conference. So we [...]

Published
2023

32. Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Tyrosine -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Stomach cancer -- Conferences, meetings and seminars, Drug approval -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ('Inhibikase' or 'Company'), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course [...]

Published
2024

33. Aesculap Chifa Sp. z o.o. secures contract for Medical equipments - Disposable medical devices for a cytotoxic drug workshop

Subjects
Medical equipment -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Physiological apparatus -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Contract agreement, News, opinion and commentary
Abstract

Poland based Aesculap Chifa Sp. z o.o. has secured contract from Uniwersytecki Szpital Kliniczny w Poznaniu for Medical equipments - Disposable medical devices for a cytotoxic drug workshop. The value [...]

Published
2023

34. Becton Dickinson Polska Sp. z o.o. secures contract for Medical equipments - Disposable medical devices for a cytotoxic drug workshop

Subjects
Becton, Dickinson and Co. -- Conferences, meetings and seminars -- Contracts, Medical equipment -- Conferences, meetings and seminars, Medical test kit industry -- Contracts -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Medical equipment and supplies industry -- Contracts -- Conferences, meetings and seminars, Physiological apparatus -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Contract agreement, News, opinion and commentary
Abstract

Poland based Becton Dickinson Polska Sp. z o.o. has secured contract from Uniwersytecki Szpital Kliniczny w Poznaniu for Medical equipments - Disposable medical devices for a cytotoxic drug workshop. The [...]

Published
2023

35. Skamex Sp. z o.o. secures contract for Medical equipments - Disposable medical devices for a cytotoxic drug workshop

Subjects
Medical equipment -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Physiological apparatus -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Contract agreement, News, opinion and commentary
Abstract

Poland based Skamex Sp. z o.o. has secured contract from Uniwersytecki Szpital Kliniczny w Poznaniu for Medical equipments - Disposable medical devices for a cytotoxic drug workshop. The value of [...]

Published
2023

36. POLMiL SP. Z O.O. secures contract for Medical equipments - Disposable medical devices for a cytotoxic drug workshop

Subjects
Medical equipment -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Physiological apparatus -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Contract agreement, News, opinion and commentary
Abstract

Poland based POLMiL SP. Z O.O. has secured contract from Uniwersytecki Szpital Kliniczny w Poznaniu for Medical equipments - Disposable medical devices for a cytotoxic drug workshop. The value of [...]

Published
2023

37. J. Chodacki, A. Misztal ,C¤Medica' Spolka Jawna secures contract for Medical equipments - Disposable medical devices for a cytotoxic drug workshop

Subjects
Medical equipment -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Physiological apparatus -- Conferences, meetings and seminars, Workshops (Educational programs) -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Contract agreement, News, opinion and commentary
Abstract

Poland based J. Chodacki, A. Misztal ǤMedica' Spolka Jawna has secured contract from Uniwersytecki Szpital Kliniczny w Poznaniu for Medical equipments - Disposable medical devices for a cytotoxic drug workshop. [...]

Published
2023

38. Menarini Group Presented Initial Safety & Efficacy Data from Phase 1b|2 ELEVATE and ELECTRA Combination Studies of ORSERDU(r) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Subjects
Stemline Therapeutics Inc. -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars -- Drug therapy, Metastasis -- Conferences, meetings and seminars -- Drug therapy, Antineoplastic agents -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars -- Drug therapy, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Orserdu (Medication)
Abstract

FLORENCE: The Menarini Group (Menarini), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (Stemline), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments [...]

Published
2023

39. Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b|2 ELEVATE and ELECTRA Combination Studies of ORSERDU(r) (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium

Subjects
Stemline Therapeutics Inc. -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Cancer patients -- Conferences, meetings and seminars -- Drug therapy, Metastasis -- Conferences, meetings and seminars -- Drug therapy, Antineoplastic agents -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Breast cancer -- Conferences, meetings and seminars -- Drug therapy, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Orserdu (Medication)
Abstract

FLORENCE: Menarini Industrie Farmaceutiche Riunite has issued the following news release: The Menarini Group ('Menarini'), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ('Stemline'), a wholly-owned subsidiary [...]

Published
2023

40. World Cancer Day Focus: AACR Annual Meeting Leads Global New Cancer Drug Trends, Domestic Drugs Lead the Trend

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Biological products -- Conferences, meetings and seminars, Viral antibodies -- Conferences, meetings and seminars, Immunotherapy -- Conferences, meetings and seminars, Antibodies -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Pharmaceutical industry -- Industry forecasts -- Conferences, meetings and seminars, Business, Business, international
Abstract

The 'Global Cancer Statistics 2022' report predicts a significant rise in new cancer cases worldwide, with Medicilon playing a crucial role in the development of ADC, small molecule targeted drugs, [...]

Published
2024

41. HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference - Final

Subjects
AstraZeneca PLC -- Conferences, meetings and seminars -- Officials and employees, Bank of America Corp. -- Officials and employees -- Conferences, meetings and seminars, Banks (Finance) -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Officials and employees -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Officials and employees, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business, Tagrisso (Medication)
Abstract

Presentation ALEC WARREN STRANAHAN, ASSOCIATE, BOFA SECURITIES, RESEARCH DIVISION: Hey, everyone. Good afternoon, and welcome to day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with [...]

Published
2023

42. Nurix Therapeutics Inc at Needham Healthcare Conference (Virtual) - Final

Subjects
Needham and Company Inc. -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Securities industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Securities industry, Business
Abstract

Presentation GIL BLUM, ANALYST, NEEDHAM & COMPANY: Good afternoon, everyone, and thank you for joining me at the fourth day of the Needham & Company Healthcare Conference. My name is [...]

Published
2023

43. Arvinas, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan112023 01:30 PM - Final

Subjects
JPMorgan Chase & Co. -- Conferences, meetings and seminars -- Officials and employees, Pfizer Inc. -- Officials and employees -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Banking industry -- Officials and employees -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars -- Officials and employees, Antimitotic agents -- Conferences, meetings and seminars, Banking industry, Business
Abstract

Presentation LUT MING CHENG, RESEARCH ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good afternoon, everyone. Thanks for joining us for another session at the 41st JPMorgan conference. I'm Brian Cheng. [...]

Published
2023

44. Rain Oncology Inc at JPMorgan Healthcare Conference - Final

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business
Abstract

Presentation UNIDENTIFIED ANALYST: Good morning, everyone. Thank you for joining us for the 41st JPMorgan Healthcare Conference. We're thrilled to have you here, and we're thrilled to have Rain Oncology. [...]

Published
2023

45. Deciphera Pharmaceuticals Inc at JPMorgan Healthcare Conference - Final

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Qinlock (Medication), Sutent (Medication)
Abstract

Presentation DANIEL G. WOLLE, ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good morning, everyone. It's my pleasure to introduce -- my name is Daniel. I'm one of the analysts on [...]

Published
2023

46. Deciphera Pharmaceuticals Inc at JPMorgan Healthcare Conference - Final

Subjects
Antineoplastic agents -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, Qinlock (Medication), Sutent (Medication)
Abstract

Presentation DANIEL G. WOLLE, ANALYST, JPMORGAN CHASE & CO, RESEARCH DIVISION: Good morning, everyone. It's my pleasure to introduce -- my name is Daniel. I'm one of the analysts on [...]

Published
2023

47. Menarini Group Announces New Data on ORSERDU (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Subjects
Stemline Therapeutics Inc. -- Conferences, meetings and seminars, Trade and professional associations -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars -- Genetic aspects -- Care and treatment, Antineoplastic agents -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Breast cancer -- Care and treatment -- Genetic aspects -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, Business, News, opinion and commentary, Orserdu (Medication), Elzonris (Medication)
Abstract

- Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients - ORSERDU data reinforce its key [...]

Published
2023

48. ACCELERATING ANTICANCER AGENT DEVELOPMENT AND VALIDATION WORKSHOP (AAADV)

Subjects
United States. Food and Drug Administration -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Cancer -- Prevention -- Care and treatment, Antimitotic agents -- Conferences, meetings and seminars, News, opinion and commentary
Abstract

SILVER SPRING, MD -- The following information was released by the U.S. Food and Drug Administration (FDA): Goals and Objectives: To expedite the development and validation processes for new anticancer [...]

Published
2023

49. Lilly's Retevmo(r) (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023

Subjects
Eli Lilly and Co. -- Conferences, meetings and seminars, Oncology, Experimental -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars, Antineoplastic agents -- Conferences, meetings and seminars, Lung cancer, Small cell -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Thyroid cancer -- Conferences, meetings and seminars, Cancer -- Research, Pharmaceutical industry -- Conferences, meetings and seminars, Antimitotic agents -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Retevmo (Medication)
Abstract

INDIANAPOLIS: Eli Lilly and Company has issued the following news release: Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo(r) [...]

Published
2023

50. Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial

Subjects
Bristol-Myers Squibb Co. -- Conferences, meetings and seminars, Ono Pharmaceutical Company Ltd. -- Conferences, meetings and seminars, Metastasis -- Conferences, meetings and seminars -- Patient outcomes -- Drug therapy, Antineoplastic agents -- Conferences, meetings and seminars, Diseases -- Relapse, Lung cancer, Small cell -- Patient outcomes -- Drug therapy -- Conferences, meetings and seminars, Immunotherapy -- Conferences, meetings and seminars, Chemotherapy -- Conferences, meetings and seminars, Lung cancer, Non-small cell -- Drug therapy -- Patient outcomes -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, Cancer -- Chemotherapy, Antimitotic agents -- Conferences, meetings and seminars, Business, Business, international, Yervoy (Medication), Opdivo (Medication)
Abstract

Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo reduced the risk of disease recurrence, progression or death by 42% in patients with resectable non-small cell lung cancer CheckMate [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results